- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Start codon.
Displaying page 1 of 1.
| EudraCT Number: 2019-004819-31 | Sponsor Protocol Number: IN-CRC-001 | Start Date*: 2021-05-19 | |||||||||||
| Sponsor Name:IN3BIO | |||||||||||||
| Full Title: A Phase I/II, multi-centre, open-label, adaptive design, umbrella study assessing the safety, tolerability, immunogenicity and efficacy of IN01 in combination with small-molecule inhibitors in two ... | |||||||||||||
| Medical condition: colorectal cancer at a metastatic stage, eligible for a second line treatment and presenting with a constitutive BRAF or RAS mutation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-005428-41 | Sponsor Protocol Number: 02044190615-01 | Start Date*: 2014-12-01 | ||||||||||||||||
| Sponsor Name:Department of experimental and clincial medicine "F. Magrassi" | ||||||||||||||||||
| Full Title: Phase III study of RegorAfenib VErsus placebo as maintenance therapy in RAS wiLd type metastatic coLOrectal cancer | ||||||||||||||||||
| Medical condition: The present proposal is aimed to evaluate the efficacy and safety of regorafenib as maintenance therapy in increasing the efficacy of the best available therapy for first line treatment fluoropirim... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2009-017384-42 | Sponsor Protocol Number: 838 | Start Date*: 2010-05-17 | |||||||||||
| Sponsor Name:Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
| Full Title: Safety and efficacy of the addition of simvastatin to cetuximab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage ... | |||||||||||||
| Medical condition: k-ras mutant advanced or metastatic colorectal cancer failing prior 5-FU, oxaliplatin, and irinotecan containing regimens. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002333-29 | Sponsor Protocol Number: GEMCAD-1601 | Start Date*: 2017-04-19 | |||||||||||
| Sponsor Name:GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo) | |||||||||||||
| Full Title: Preoperative induction therapy with 12 weeks of Panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third wit... | |||||||||||||
| Medical condition: Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-014452-30 | Sponsor Protocol Number: 30012009 | Start Date*: 2010-03-29 | |||||||||||
| Sponsor Name:Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
| Full Title: Safety and efficacy of the addition of simvastatin to panitumumab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stag... | |||||||||||||
| Medical condition: k-ras mutant advanced or metastatic colorectal cancer failing prior 5FU, oxaliplatin and irinotecan containing regimens | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-020240-35 | Sponsor Protocol Number: 2010-020240-35 | Start Date*: 2010-07-09 | ||||||||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | ||||||||||||||||||
| Full Title: Significance of the FSH receptor polymorphism p.N680S for the efficacy of FSH therapy of idiopathic male infertility: a pharmacogenetic approach. | ||||||||||||||||||
| Medical condition: Idiopathic male infertility | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male | |||||||||||||||||
| Trial protocol: IT (Completed) DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-001642-28 | Sponsor Protocol Number: INCB39110-205 | Start Date*: 2015-09-28 | |||||||||||||||||||||
| Sponsor Name:Incyte Corporation | |||||||||||||||||||||||
| Full Title: A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer Whose Tu... | |||||||||||||||||||||||
| Medical condition: Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, e... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2021-001696-16 | Sponsor Protocol Number: SOLUCOM | Start Date*: 2021-10-28 | ||||||||||||||||||||||||||
| Sponsor Name:Vestre Viken Health Trust | ||||||||||||||||||||||||||||
| Full Title: Sotorasib in advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities | ||||||||||||||||||||||||||||
| Medical condition: Advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: NO (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.